

POLICY NAME	Nexviazyme (alglucosidase alfa-ngpt)	POLICY #	3047P
--------------------	--------------------------------------	-----------------	-------

Criteria

Coverage Criteria

- ☐ Diagnosis of late-onset Pompe disease as supported by the following:
 - Enzyme assay showing a deficiency of acid alpha-glucosidase (GAA) activity in the blood, skin, or muscle
 - Genetic testing showing a mutation in the GAA gene
- ☐ Age 1 year or older
- ☐ Prescribed by a Geneticist or specialist in Pompe disease
- ☐ Imaging rules out presence of cardiac hypertrophy
- ☐ Documentation showing baseline percent-predicted forced vital capacity (FVC) and 6-minute walk test (6MWT)
- ☐ Review of chart notes documenting diagnosis and confirming that patient has met all above requirements for treatment with Nexviazyme by both a pharmacist and medical director

Exclusion Criteria – Any of the following prevents coverage

- ☐ Concomitant use with Lumizyme is considered a duplication of therapy and excluded from coverage